trial

A Comparative Study of New Medications for Psychosis in Adolescents

NCTId NCT00222495
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
— · Completed
Enrollment 30
Sponsored by University of Minnesota
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Completed
Enrollment
30
Study type
Interventional
Allocation
Randomized
Model
Single Group
Masking
None
Start
2002-08
Primary completion
—
Eligibility
ALL · 12 Years · 18 Years

Interventions & indications

Drugs
QuetiapineOlanzapineRisperidone

Sponsors

University of MinnesotaLead Sponsor
AstraZenecaCollaborator
Jensen, Jonathan B., M.D.Collaborator

Investigators

2
Jonathan K Wynn, Ph.D.Principal Investigator
S. Hossein Fatemi, M.D., Ph.D.Study Director

Sites

1 total
Minneapolis, United States

Facts & assertions

3 sourced
Enrollment
30
Phase
NA
Status
COMPLETED
relationships
The graph out of here
drug
Quetiapine
drug
Olanzapine
drug
Risperidone
drug
lead_sponsor
University of Minnesota
company
collaborator
AstraZeneca
company
Jensen, Jonathan B., M.D.
company
indication
Schizophreniform Disorders
indication
Psychotic Disorders
indication
Psychotic Disorders
indication
investigator
Jonathan K Wynn, Ph.D.
person
S. Hossein Fatemi, M.D., Ph.D.
person